Support The World's Smartest Network

Help the New York Academy of Sciences bring late-breaking scientific information about the COVID-19 pandemic to global audiences. Please make a tax-deductible gift today.

This site uses cookies.
Learn more.


This website uses cookies. Some of the cookies we use are essential for parts of the website to operate while others offer you a better browsing experience. You give us your permission to use cookies, by continuing to use our website after you have received the cookie notification. To find out more about cookies on this website and how to change your cookie settings, see our Privacy policy and Terms of Use.

We encourage you to learn more about cookies on our site in our Privacy policy and Terms of Use.

Synthetic Approaches to Tetracyclines and Mechanisms of Resistance

Synthetic Approaches to Tetracyclines and Mechanisms of Resistance

Wednesday, November 30, 2005

The New York Academy of Sciences

Presented By


Organizers: Tarek Mansour and Magid Abou-Gharbia, Wyeth Research

Recent years have seen an increasing level of dialogue between chemists and biologists, the lines of communication consolidated by the availability of recombinant biotechnology tools for manipulating the chemical structure of genes, and the proteins they encode. This has led to an explosion of interdisciplinary activity at the chemistry/biology interface, now coined chemical biology. Meetings of this group provide a forum for lively discussion and for establishing connections, and perhaps collaborations, between chemists armed with novel technologies and biologists receptive to using these approaches to solve their chosen biological problem.


Yi Tang, UCLA
"Tetracycline Biosynthesis: Gene Cluster Information and Early Reconstitution Studies."

Phaik-Eng Sum, Wyeth Research
"The Discovery of Tygacil : Representative of a New Class of Antibacterial Agents - Glycylcyclines."

Patricia Bradford, Wyeth Research
"Tygacil, a Novel Glycylcycline Antibiotic: Mechanisms of Action, Antibacterial Activity and Mechanisms of Resistance."


"Tetracycline Biosynthesis: Gene Cluster Information and Early Reconstitution Studies"
Yi Tang

Tetratracyclines are aromatic polyketides biosynthesized by bacterial type II polyketide synthases (PKSs). Understanding the biochemistry of tetracycline PKSs is important towards the rational and combinatorial manipulation of tetracycline biosynthesis. Towards this end, we have sequenced the entire gene cluster of oxytetracycline (oxy, otc) PKS from Streptomyces rimosus. Sequence analysis revealed a total of twenty-one genes within the otrA and otrB resistance genes. In vivo reconstitution using Streptomyces coelicolor revealed that the minimal PKS and a novel amidotransferase, OxyD, are necessary and sufficient for the biosynthesis of amidated polyketides. A novel alkaloid (WJ35) was synthesized as the major product when the oxy minimal PKS, the C9 ketoreductase (OxyJ) and OxyD were coexpressed in S. coelicolor. WJ35 is an isoquinolone compound derived from an amidated decaketide backbone and cyclized with novel regioselectivity. Coexpression of additional oxy biosynthetic enzymes further tailored the amidated tetracycline backbone into novel chemical scaffolds.

"The Discovery of Tygacil : Representative of a New Class of Antibacterial Agents - Glycylcyclines"
Phaik-Eng Sum

Tetracyclines have been used therapeutically as broad-spectrum antibiotics since 1948. The emergence of drug-resistant bacteria has posed a growing challenge to public health and underscored the need for new antibiotics for the treatment of drug resistant infections. A semi-synthetic program was initiated to identify new derivatives with activity against tetracycline-resistant strains. We reasoned that peptidic attachment at ring D, especially at the 9-position might enhance permeation while maintaining ribosome binding. The strategy of using 9-amino-mino as starting point for the synthesis provided accessibility to a number of new derivatives for structure-activity relationship study. This led to the design and synthesis of a series of novel compounds that have been referred to as glycylcycline. One of the glycylcyclines, Tygacil (also known as tigecycline, GAR-936 or TBG-MINO) was selected for further development. It has an expanded broad-spectrum of antibacterial activity both in vitro and in vivo. It is active against bacterial strains carrying either or both of the two major forms of tetracycline resistance (efflux and ribosomal protection). Most importantly, it is active against the multiply antibiotic resistant gram-positive pathogenic bacteria, especially methicillin resistant Staphylococcus aureus (MRSA) (MIC 0.5 microg/ml), vancomycin resistant enterococci